EUCTR2019-001549-42-GB进行中（未招募）1 期
A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis. - StarMS
Sheffield Teaching Hospitals0 个研究点目标入组 198 人开始时间: 2020年2月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 198
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of MS using the 2017 McDonald criteria.
- •2. Age 16-55 inclusive.
- •3. EDSS 0-6.0 inclusive*. If the EDSS score is 6.0 this must be due to confirmed relapse rather than progressive disease.
- •4. Severe inflammatory disease defined as RRMS course with 2 or more protocol defined relapses, or 1 such relapse and evidence of MRI disease activity >3 months before or after its onset, in last 12 months despite being on a DMT*.
- •5. Clinical stability for >30 days following last relapse at the time of screening.
- •6. Satisfactory EBMT Autoimmune Disease Working Party (ADWP) recommended screening assessment prior to aHSCT.
- •7. Participants who have been reviewed by the central neurology team and confirmed as eligible.
- •8. Participants who, in the opinion of the local haematology lead or delegate, are fit enough to undergo treatment.
- •9. Able to undergo MRI examination.
- •* Patients with EDSS scores of 0-1.5 or those who failed only first line treatments must also fulfil following criteria: short illness duration (<5 years), active disease clinically and radiologically (i.e. at least 2 relapses in the last 12 months and evidence of multiple Gad enhancing MRI lesion), high brain lesion load and brain or spinal cord atrophy.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 178
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Diagnosis of primary or secondary progressive MS.
- •2. Disease duration of >10 years from symptom onset (note: symptoms must be clearly attributable to MS).
- •3. Previous use of alemtuzumab, ocrelizumab or cladribine.
- •4. Previous HSCT for any reason, or any previous experimental or commercial stem cell therapy.
- •5. JCV antibody Index of >1.5 in patients previously treated with natalizumab (unless they are CSF JCV PCR negative).
- •6. Prior diagnosis of Hepatitis B, Hepatitis C or HIV infection or current TB infection.
- •7. Pregnant or breast-feeding females.
- •8. Unwilling to use adequate contraception during the trial. Female participants of child-bearing potential must be willing to use adequate contraception for the duration of the trial (24 months). Male participants with female partners of child-bearing potential must be willing to use adequate contraception if they are randomised to the aHSCT arm until at least 6 months after discontinuation of cyclophosphamide.
- •9. Unable to comply with treatment protocol.
- •10. Contraindication to the use of cyclophosphamide, G-CSF (filgrastim or lenograstim) or rabbit ATG.
- •11. Participants with significant medical co-morbidity that precludes aHSCT as assessed by the local haematology team.
- •12. Significant language barriers, which are likely to affect the participant’s understanding of the study, or ability to complete outcome questionnaires.
- •13. Concurrent participation in another interventional clinical trial.
- •14. AST and ALT >2.5 x upper limit of normal (ULN), bilirubin > 1.5 x ULN or direct bilirubin >ULN for participants with total bilirubin levels >1.5 x ULN
- •15. Current diagnosis of a clinically defined bleeding disorder (patients with platelet counts of 100x109/l or above up to normal range are not excluded, as per section 18d. Persistently abnormal coagulation tests should be addressed to determine whether they constitute a defined bleeding disorder).
- •16. Current diagnosis of a clinically defined autoimmune disorder other than multiple sclerosis. (i.e. meeting full current international clinical and laboratory criteria for a specific autoimmune disorder).
- •17. Patients with history of myocardial infarction, angina pectoris, stroke or arterial dissection
- •18. Participants who are not considered medically fit for aHSCT defined by any of the following. Note that these criteria are not automatic exclusion criteria but if any of these criteria are met, and in the opinion of the PI the participant is medically fit enough to undergo aHSCT, the case may be put forward to the central team for discussion about eligibility:
- •a.Renal: creatinine clearance <40ml/min (measured or estimated)
- •b.Cardiac: clinical evidence of refractory congestive heart failure, left ventricular ejection fraction <45% by cardiac echo; uncontrolled ventricular arrhythmia; pericardial effusion with haemodynamic consequences as evaluated by an experienced echo cardiographer
- •c.Concurrent neoplasms or myelodysplasia
- •d.Bone marrow insufficiency defined as neutropenia with an absolute neutrophil count <1x109/l, or thrombocytopenia with a platelet count <100x109/l, or anaemia with a haemoglobin <100g/l
- •e. Diagnosis of hypertension, which is uncontrolled despite at least 2 anti-hypertensive agents.
- •f.Uncontrolled acute or chronic infection with any infection the investigator or central team consider a contraindication to participation. (N.B. Baseline JC virus serology will be recorded, but positivity w
研究者
相似试验
已完成
不适用
The Early Nasojejunal Tube to Meet Energy Requirements in Intensive Care StudyMechanically-ventilated, medical-surgical critically ill patients with reduced gastric motilityOther - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12605000149662ICU Rsearch Department, The Alfred Hospital, Melbourne Victoria180
进行中（未招募）
1 期
Transplant Antibody-mediated Rejection: Guiding Effective Treatments-1 (TAR:GET-1)EUCTR2018-002882-20-GBImperial College London170
进行中（未招募）
3 期
A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna (LM) when staged surgical excision with 5mm margins is not possible, is refused, or fails.entigo maligna (LM)Lentigo maligna (LM)Cancer - Non melanoma skin cancerACTRN12615000266561Melanoma and Skin Cancer (MASC) Trials126
已完成
不适用
ugol’s Iodine in surgical management of epithelial dysplasia in the oral cavity and oropharynxEpithelial dysplasia in the oral cavity and oropharynxCancerISRCTN11348079HS Greater Glasgow and Clyde40
招募中
不适用
A multicenter randomized controlled trial to evaluate overall morbidity after total minimally invasive esophagectomy versus hybrid esophagectomyC15.9Oesophagus, unspecifiedDRKS00027927Klinik für Allgemeine, Viszeral- und Transplantationschirurgie Universitätsklinikum Tübingen152